Agenus Inc. has announced the closing of a $141 million strategic collaboration with Zydus Lifesciences Ltd. The agreement aims to accelerate the global development and potential commercialization of Agenus’ botensilimab and balstilimab (BOT+BAL) immunotherapy combination program. As part of the deal, Zydus will pay Agenus $75 million in cash for the transfer of biologics manufacturing facilities in California and will make a $16 million equity investment. Additionally, Agenus is eligible for up to $50 million in milestone payments and will receive a 5% royalty on net sales of BOT and BAL in India and Sri Lanka, where Zydus will hold exclusive development and commercialization rights. The partnership also secures long-term U.S. manufacturing capacity to support Agenus’ clinical and commercial activities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260115092151) on January 15, 2026, and is solely responsible for the information contained therein.